Every recall we track for Aurobindo Pharma USA Inc — 59 in all — plus the complaints and injury reports the public filed about them.
Aurobindo Pharma USA recalls 10mg Dicyclomine Hydrochloride Capsules (1,000 bottles) after reports of empty capsules. This prescription drug was distributed by Aurobindo Pharma USA, Inc. in New Jersey.
Aurobindo Pharma recalls 325mg acetaminophen tablets with brown surface discoloration due to manufacturing issues. Consumers should check NDC 72288-405-10 and lot number AEF124004A for affected products.
Aurobindo Pharma recalls 60mg Cinacalcet tablets with N-nitroso impurity above FDA limits. Rx-only medication affected by specific lot numbers and packaging. Consumers should contact pharmacy for details.
Aurobindo Pharma recalls 3.75mg Clorazepate tablets with yellow spots due to discoloration. Rx-only medication distributed in India. Check NDC numbers and expiration dates for affected lots.
Aurobindo Pharma recalls 0.5mg Rasagiline Tablets (30-count) due to failed dissolution testing. This may affect drug effectiveness. Check NDC 0378-1270-93 and lot 3112444.
Aurobindo Pharma USA Inc. recalls 200mg Rufinamide Tablets (120-count) due to cGMP deviations in batch production. This recall affects prescription-only medication distributed in the US. No specific action steps are listed in the official notice.
Aurobindo Pharma USA Inc. recalls 400mg Rufinamide Tablets (120-count) due to cGMP deviations in batch production. This recall follows release of the batch before regulatory approval. No specific action steps are listed in the official notice.
Aurobindo Pharma USA Inc. recalls 500mg acetaminophen caplets with discoloration issues. Products may contain impurities affecting safety. Consumers should check lot numbers and contact the company for details.
Aurobindo Pharma USA recalls 20mg/12.5mg Quinapril and Hydrochlorothiazide tablets due to N-Nitroso-quinapril impurity exceeding safe levels. Consumers should check NDC 65862-162-90 and lots QE2021005-A/QE2021010-A.
Aurobindo Pharma recalls cyanocobalamin injection vials with subpotent drug levels. These injections may not contain enough active ingredient for effective treatment. Affected lots manufactured in India for specific expiration dates.
Aurobindo Pharma recalls 0.5% moxifloxacin eye drops due to impurities that could cause eye injury. Affected lots from India, expiring June 2023. Stop using immediately.
Aurobindo Pharma recalls 45mg Pioglitazone tablets with failed specifications that may be superpotent. Consumers should check NDC 57237-221-05 and batch numbers PF4520028A/B for affected products.
Aurobindo Pharma USA Inc. recalls 6.25 mg Carvedilol tablets (NDC 65862-143-05) due to failed impurities and degradation specifications. This Rx-only medication was distributed from 279 Princeton-Hightstown Road, East Windsor, NJ.
Aurobindo Pharma recalls 100mg Metoprolol Tartrate tablets due to metal wire found in one tablet. This could cause injury if swallowed. Contact for return instructions.
Aurobindo Pharma recalls 500-tablet sulfamethoxazole-trimethoprim (800mg/160mg) prescription medication due to potential metal contamination. This recall affects specific batches made in India with NDC 65862-420-05.
